Abstract:Abstract Background: Angiogenesis is critical for breast cancer progression. Within tumors, non-neoplastic cells assist tumor growth by producing growth factors and pro-angiogenic cytokines. Studies have demonstrated that tumor-associated macrophages (TAMs) are recruited to tumors before malignant conversion and are essential for promoting angiogenesis. We sought to study the role that macrophage phenotype—classically activated (M1) and alternatively activated (M2)—plays in the subsequent activation of the angiogenic pathway, with the goal of understanding the mechanisms underlying angiogenesis in the different molecular subtypes of breast cancer.Methods: 128 matching breast tumors, DCIS and normal tissues were obtained from the University of Chicago Breast Cancer SPORE tissue bank under IRB approved protocols. Tissue microarrays were constructed and molecular subtype was assigned based on immunohistochemical (IHC) staining into the following groups: luminal A (ER+, PR+, HER2-), luminal B (ER+, HER2+ or ER+, PR-), HER2-like (ER-, HER2+) and basal-like (ER-, HER2-, EGFR+ and/or CK5/6+). Macrophage phenotype was determined using double staining with CD68/CD163 (M2) and CD68/CD80 (M1). Microvessel density (MVD) was measured by IHC staining using anti-CD34. Staining quantification was performed independently by two pathologists. To control for intra-individual correlation, linear mixed-effects models were used to compare differences in % of M1 and M2 with disease progression. To evaluate the association of MVD with % of M1 and M2, bivariate plots were generated and Pearson's correlation coefficients were calculated. Spearman's correlation coefficients were used for the correlation between macrophage phenotype and tumor stage and grade. The Kaplan-Meier method was used to calculate overall survival.Results: Of the tumors studied, 88% were stage I-II. 17% were grade 1, 39% grade 2 and 44% grade 3. 70 were luminal A, 36 basal-like, 9 HER2-like and 6 luminal B. The ratio of M2:M1 increased with disease progression from normal breast to DCIS to invasive cancer (p<0.001). Increased M2% was associated with high tumor grade, increased MVD and decreased overall survival (all p<0.001). M1% was associated with low tumor grade (<0.001), but was not significantly associated with MVD or overall survival. Both the HER2-like and basal-like subtypes have significantly higher % M2 as compared to the luminal A subtype (p<0.001).Discussion: There are several studies which suggest that activated TAMs are responsible for the secretion of pro-angiogenic cytokines which stimulate neovascularization. To our knowledge, this is the first study that has correlated macrophage phenotype to breast molecular subtype and MVD in human breast tumors. Our findings suggest that the M2 macrophage phenotype is associated with aggressive histopathologic features and poor clinical outcome. Inhibiting the M2 macrophage may prevent the release of pro-angiogenic factors, and might be an effective approach at preventing neovascularization and improving patient outcomes. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 107.

New Insights into M1/M2 Macrophages: Key Modulators in Cancer Progression

Tumor-Associated Macrophages in Tumor Immunity (vol <i>11</i>, <i>583084</i>, <i>2020</i>)

M2 macrophages are the origin of tumor metastasis

Polarization of Cancer-Associated Macrophages Maneuver Neoplastic Attributes of Pancreatic Ductal Adenocarcinoma

The role of macrophages-mediated communications among cell compositions of tumor microenvironment in cancer progression

Macrophage polarization in the tumor microenvironment: Emerging roles and therapeutic potentials

Tumor-Associated Macrophage Subsets: Shaping Polarization and Targeting

A Double Feedback Loop Mediated by Microrna-23A/27a/24-2 Regulates M1 Versus M2 Macrophage Polarization and Thus Regulates Cancer Progression

[Research Progress of Interaction Between CAFs and M2 Macrophages to Promote Tumor Progression].

Tumor‑infiltrating M2macrophages Driven by Specific Genomic Alterations Are Associated with Prognosis in Bladder Cancer

Macrophage Diversity Enhances Tumor Progression and Metastasis

Tumor Cell-Derived Microparticles Polarize M2 Tumor-Associated Macrophages for Tumor Progression.

The prognostic role of M2 tumor-associated macrophages in non-small-cell lung cancer.

The Tumor-Associated Macrophage-M2-Cancer Cell Complex and the Observation of Heterogeneous Modification of the Morphological Structure of Lung Adenocarcinoma

MicroRNAs in Tumor Immunity: Functional Regulation in Tumor-Associated Macrophages.

Roles of Tumor-Associated Macrophages in Tumor Progression: Implications on Therapeutic Strategies

The pleiotropic mode and molecular mechanism of macrophages in promoting tumor progression and metastasis

The M2/Alternatively Activated Macrophage Phenotype Correlates with Aggressive Histopathologic Features and Poor Clinical Outcome in Early Stage Breast Cancer.

Tumor-Associated Macrophages: Recent Insights and Therapies

From Dichotomy to Diversity: Deciphering the Multifaceted Roles of Tumor-Associated Macrophages in Cancer Progression and Therapy.

New insights into the role of macrophages in cancer immunotherapy